OWA
TEVA icon

Opal Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Opal Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,293
Closed -$69.1K – 542
2026
Q1 		$69.1K Buy
+2,293
New +$73.8K 0.02% 347

Other funds holding TEVA

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

Opal Wealth Advisors's TEVA Position: Q2 2026 in Review

Opal Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 2,293 shares — an estimated $69.1K sold.

Opal Wealth Advisors first reported a position in TEVA in Q1 2026 and held it in 1 quarter. The position peaked at $69.1K in Q1 2026. 89 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Opal Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Opal Wealth Advisors sold 2,293 Teva Pharmaceuticals shares in Q2 2026, an estimated $69.1K.
  • Opal Wealth Advisors first reported a position in Teva Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Opal Wealth Advisors's Teva Pharmaceuticals position peaked at $69.1K in Q1 2026.
  • 89 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Opal Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.